Annals of Oncology Advance Access published online on April 13, 2007
Annals of Oncology, doi:10.1093/annonc/mdm087
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands
1 Department of Public Health, Erasmus MC University Medical Centre Rotterdam, Rotterdam
2 Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Eindhoven
3 Department of Dermatology, Erasmus MC University Medical Centre Rotterdam, Rotterdam
4 Department of Surgical Oncology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands
* Correspondence to: Dr E. de Vries, Department of Public Health, Erasmus MC University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Tel: +31-10-4087730; Fax: +31-10-4638475; E-mail: e.devries{at}erasmusmc.nl
Background: We present survival outcomes of patients registered in the Dutch population-based Eindhoven Cancer Registry (ECR).
Patients and methods: Data on patients diagnosed with a melanoma between 1980 and 2002 were obtained from the ECR. Data on vital status up to 1 January 2005 were obtained, up-to-date survival rates were calculated using period analysis. Multivariate analyses were carried out using Cox proportional hazards model.
Results: Ten-year crude survival rates were 82% for women and 60% for men (P < 0.05). Thin melanomas (Breslow thickness 
2.0 mm) had 5-year crude survival rates >74%, for melanomas >4.0 mm these rates were <65% (P < 0.05). In the early 1980s, 5-year relative survival rates were 84% and 62% for young (<60 years) women and men, and 66% and 69%, respectively, for the elderly (aged 60+). In the period 2000–2002, these rates had improved to >90% for females and to >72% for males. Multivariate analyses showed increased hazard ratios with increasing age and Breslow thickness, being male, having a melanoma on the trunk or unknown sites and having a nodular melanoma.
Conclusions: Despite the absence of improvements in treatment options for melanoma, survival improved significantly, except for elderly males.
crude survival, cutaneous malignant melanoma, period analysis, population-based, relative survival
Received for publication August 15, 2006. Revision received January 23, 2007. Accepted for publication February 12, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Cornish, C. Holterhues, L. V. van de Poll-Franse, J. W. Coebergh, and T. Nijsten A systematic review of health-related quality of life in cutaneous melanoma Ann. Onc., August 1, 2009; 20(suppl_6): vi51 - vi58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Koomen, A. Joosse, R. M. C. Herings, M. K. Casparie, H. J. Guchelaar, and T. Nijsten Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study Ann. Onc., February 1, 2009; 20(2): 358 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. de Vries, T. E. C. Nijsten, O. Visser, E. Bastiaannet, S. van Hattem, M. L. Janssen-Heijnen, and J. -W. W. Coebergh Superior survival of females among 10 538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site Ann. Onc., March 1, 2008; 19(3): 583 - 589. [Abstract] [Full Text] [PDF]
|
|